Stocks in the NewsMost Active StocksPercent GainersPercent LosersFollowed Stocks
,

Latest News

There's a 35% Chance That the Fed Hikes Rates at Least 4 Times by September 2027, Which Can Decimate the AI-Driven Bull Marketfool.com
An aggressive rate-hiking cycle might be just the catalyst needed to send a historically pricey stock market past its tipping point.
Via The Motley Fool · October 16, 2026
Sandisk Stock Could Be Worth $4,128 in the Next Yearfool.com
There are risks, but the CEO sees a long runway of growth.
Via The Motley Fool · October 16, 2026
Corpay MAAnnouncement: Volatus Aerospace Targets AISPECO in $13M Aerial Tech Dealmarketbeat.com
Volatus Aerospace said it has signed an agreement to acquire 100% of Lithuania-based technology company AISPECO, a transaction intended to expand its aerial intelligence capabilities across commercial infrastructure, defense, security and drone applications. The proposed deal has base consideration
Via MarketBeat · October 16, 2026
Deckers Outdoor (NYSE:DECK): A GARP Stock With Debt-Free Growth and Attractive Valuationchartmill.com
Via Chartmill · October 16, 2026
Paysign (NASDAQ:PAYS) Shows High-Growth Leadership and Strong Momentumchartmill.com
Via Chartmill · October 16, 2026
Hamilton Lane (NASDAQ:HLNE): A GARP Candidate Built for Growth at a Reasonable Pricechartmill.com
Via Chartmill · October 16, 2026
Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setupchartmill.com
Via Chartmill · October 16, 2026
Micron Stock Is 25% Below Its June Record. Is It a Buy Now?fool.com
The memory maker now sees more earnings a quarter than it did when its shares peaked. Has the sell-off been overdone?
Via The Motley Fool · October 16, 2026
Buffett's Berkshire Is Going Long on Homebuilders. Here's Why I'm Moving in the Opposite Directionfool.com
Berkshire is moving into the homebuilding industry, but high mortgage rates have hurt the sector.
Via The Motley Fool · October 16, 2026
Schwab's Dividend ETF Has Gained 25% This Year. Is It Still Worth Buying?fool.com
Its payout has hardly risen this year, but its price has surged. What does that leave for the next five years?
Via The Motley Fool · October 16, 2026
Here's How Much the Average Social Security Check Could Increase in 2027 With a 3.6% COLAfool.com
Benefits could get a nice boost, but some seniors may not get their increase in full.
Via The Motley Fool · October 16, 2026
Innodata vs. Nebius: Here's What Revenue Trends Tell Investors About These Artificial Intelligence Companiesfool.com
Nebius has tripled revenue in just two years while Innodata grew at a steadier pace, but the gap between them tells a more nuanced story about growth trajectories.
Via The Motley Fool · October 16, 2026
Erdene’s Zuun Mod PEA Targets $745M NPV, 34-Year Molybdenum-Copper Minemarketbeat.com
Erdene Resource Development (TSE:ERD) said its preliminary economic assessment (PEA) for the wholly owned Zuun Mod Molybdenum-Copper Project in southwestern Mongolia outlines a potential large-scale operation with an after-tax net present value of $745 million at an 8% discount rate under its base-c
Via MarketBeat · October 16, 2026
CrowdStrike vs. ServiceNow: Comparing Revenue Trends Between These Growing Software Giantsfool.com
ServiceNow commands a 2.7x revenue lead, yet both companies have posted eight consecutive quarters of growth without a single sequential decline.
Via The Motley Fool · October 16, 2026
Here's What History Says Q4 Will Bring for Chipotle (CMG) Stockfool.com
With shares trading 56% off their peak, investors hope the rest of this year tells a different story.
Via The Motley Fool · October 16, 2026
Bill Ackman Is Directing Up to $3 Billion Into Howard Hughes' Insurance Arm, Vantage, as Part of His Plan to Build a Modern Berkshire Hathaway. Is HHH Stock the Way to Play His Buffett Ambitions?fool.com
The billionaire investor has unveiled his "master plan" to diversify this master planned community developer into an insurance and investment holding company.
Via The Motley Fool · October 16, 2026
Here's What a $1,500, $2,000, and $3,000 Social Security Check Will Become After the 2027 Cost-of-Living Adjustment (COLA)fool.com
Retirees will appreciate the bump, but is it enough?
Via The Motley Fool · October 16, 2026
SCHW Q3 Deep Dive: Client Engagement and AI Initiatives Face Market Skepticism
Financial services giant Charles Schwab (NYSE:SCHW) met Wall Street’s revenue expectations in Q3 2026, with sales up 16.9% year on year to $7.17 billion. Its...
Via StockStory · October 16, 2026
FHN Q3 Deep Dive: Mortgage Portfolio Sale Reshapes Balance Sheet and Unlocks Growth Capacity
Regional banking company First Horizon (NYSE:FHN) missed Wall Street’s revenue expectations in Q3 2026, with sales falling 1.1% year on year to $883 million....
Via StockStory · October 16, 2026
MRSH Q3 Deep Dive: AI, Consulting, and Efficiency Initiatives Drive Outperformance
Professional services firm Marsh (NYSE:MRSH) reported Q3 2026 results topping the market’s revenue expectations, with sales up 8.1% year on year to $6.86 bil...
Via StockStory · October 16, 2026
MAN Q3 Deep Dive: Leadership Transition and Strategic Transformation Shape Outlook
Workforce solutions provider ManpowerGroup (NYSE:MAN) met Wall Street’s revenue expectations in Q3 2026, with sales up 4.4% year on year to $4.84 billion. It...
Via StockStory · October 16, 2026
USB Q3 Deep Dive: Fee Diversification and Deposit Growth Support Momentum
Financial services giant U.S. Bancorp (NYSE:USB) met Wall Street’s revenue expectations in Q3 2026, with sales up 9.5% year on year to $8.04 billion. Its non...
Via StockStory · October 16, 2026
XRP Treasury Company Evernorth Just Went Public on Nasdaq. Here's How It Could Impact the Price of XRP.fool.com
New digital asset treasury companies, no matter how big they become, are unlikely to boost the price of XRP.
Via The Motley Fool · October 16, 2026
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Pathmarketbeat.com
enGene (NASDAQ:ENGN) used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle
Via MarketBeat · October 16, 2026
Micron Is Down 23% From Its High. History Suggests This Is What Happens Next.fool.com
Micron has a long history of volatility. What does the current drawdown mean for investors?
Via The Motley Fool · October 16, 2026